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This clinical review has been developed for The BMJ in
collaboration with BMJ Best Practice, based on a regularly
updated web/mobile topic that supports evidence-based
decision making at the point of care. To view the complete
and current version, please refer to the Ebola virus infection
topic on the BMJ Best Practice website.
Ebola virus disease is a severe, often fatal, zoonotic filovirus
infection (fig 1⇓). There are five species: Zaire ebolavirus,
Sudan ebolavirus, Taï Forest ebolavirus, Bundibugyo
ebolavirus, and Reston ebolavirus.1
Zaire ebolavirus is responsible for the current outbreak in west
Africa, the largest outbreak since the virus was discovered in
1976 (fig 2⇓).
Transmission occurs by close contact with body fluids of
infected patients. The incubation period after infection is usually
5-9 days, with a range of 1-21 days in 95% or more of patients,2 3
and patients are not considered infectious until they develop
symptoms. The initial presentation is non-specific, whichmakes
early clinical diagnosis difficult. Human infection carries a high
case fatality rate depending on the species of Ebola virus and
quality of supportive care available.4 5
Ebola virus infection (formerly Ebola haemorrhagic fever) is
part of a group of diseases known as viral haemorrhagic fevers.6
What causes it?
The virus is thought to be initially acquired by exposure to body
fluids or tissue from infected animals, such as bats and
non-human primates; however, the natural reservoir and mode
of transmission to humans has not been confirmed.7 8 Laboratory
testing of reservoir competence shows that successful infection
is possible in bats and rodents, but not in plants or arthropods.9-12
Animal to human transmission may occur during hunting and
consumption of the reservoir species or infected non-human
primates. The practice of butchering or eating bush meat or food
contaminated with bat faeces (three species of tree roosting bats
have been implicated as a reservoir) is also thought to contribute.
Human to human transmission occurs through contact with body
fluids from infected patients.13 In early epidemics, the re-use of
non-sterile injections was responsible for many healthcare
associated transmissions.14 However, although this remains a
risk, most cases result from close physical contact or contact
with body fluids (such as sweat, blood, faeces, vomit, saliva,
genital secretions, urine, and breast milk) of infected patients.
In a study of viral shedding in various body fluids, Ebola virus
was isolated from saliva, breast milk, stool, tears, and semen
up to 40 days after the onset of illness,15-17 confirming the
possibility of delayed sexual transmission. Virus may be found
in urine during recovery, and the duration of this phenomenon
needs further study.18
Infection through inhalation is possible in non-human primates,
but there is no evidence for airborne transmission in humans.19
Outside endemic areas, Ebola virus infection is rare and is
usually imported.20Travellers from affected areas, and laboratory
scientists and others working with potentially infected materials
and animals, are at high risk.
What is the pathophysiology of this
infection
Although there have been major advances in elucidating the
pathogenesis of Ebola virus infection, most of the studies were
performed in non-human primate and rodent models.8 This is
because of the difficulties in conducting human studies in poorly
resourced settings where these infections naturally occur.
The virus genome consists of a single 19 kb strand of negative
sense RNA with seven viral genes that are transcribed by the
viral RNA dependent RNA polymerase present in the virion.
The single strand of RNA is covered by helically arranged viral
nucleoproteins NP and VP30, which are linked by matrix
proteins VP24 and VP4 to the lipid bilayer that coats the virion.21
Tissue invasion occurs through infected fluid coming into
contact with breaks in the mucosa or skin. This can occur with
animal to human or human to human transmission. Monocytes,
macrophages, and dendritic cells are the preferred replication
sites for filoviruses on initial infection. Infected cells migrate
to the regional lymph nodes, liver, and spleen, thereby
disseminating the infection. Ebola virus has a wide cell tropism
and can infect a variety of cell types.8 21 It also has the
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The bottom line
• Ebola virus disease is a severe, often fatal, zoonotic infection caused by a virus of the Filoviridae family (genus Ebolavirus)
• Human to human transmission occurs through contact with body fluids from infected patients. The incubation period after infection is
1-21 days and patients are not considered infectious until they develop symptoms
• Initial stages of infection are non-specific, which makes the differential diagnosis broad. A history of exposure and clinical suspicion
of infection should prompt isolation
• Management is currently focused on supportive care and infection control. Healthcare workers should familiarise themselves with
local guidance
• Case fatality rates range from 30% to 90%
• Because of the high likelihood of infected people travelling, all countries should have tested and practised protocols ready for screening
and managing patients
remarkable ability to modulate the expression of genes involved
in the host immune response, causing lymphocyte apoptosis
and attenuation of the protective effects of interferon.22 23
The host immune response is crucial and dictates the outcome
of infection. Progression to severe disease occurs when the virus
triggers expression of a host of pro-inflammatory cytokines,
including interferons; interleukins (ILs) such as IL-2, IL- 6,
IL-8, and IL-10; interferon inducible protein; and tumour
necrosis factor α (TNF-α).8-24 This causes endothelial activation
and reduced vascular integrity, release of tissue factor (with
associated onset of coagulopathy), and increased nitric oxide
levels (with associated hypotension).25 Thrombocytopenia is
most commonly caused by loss of platelets from damaged tissue
or more generalised virus induced disseminated intravascular
coagulation, where coagulation factors are depleted.26
Disseminated intravascular coagulation, alongwith acute hepatic
impairment, predisposes the patient to bleeding complications.
Other complications of severe disease include acute kidney
injury, hepatitis, and pancreatitis.21An early antibody response,
along with reduced lymphocyte depletion, is associated with
effective viral clearance and survival.16
The development of shock is still not well understood. Many
factors may contribute, including bacterial sepsis, possibly
through gut translocation of bacteria; a direct effect of the virus;
disseminated intravascular coagulation; and haemorrhage.23
How are people at risk identified?
Ebola virus infection is transmitted mainly through close
physical contact with infected patients. There is no evidence of
a risk of infection before symptoms develop, but late diagnosis
delays effective patient isolation, allowing for potential
transmission of the infection among contacts. Screening and
active case finding are therefore essential to avoid or stop an
epidemic.
Early diagnosis hinges on identifying patients who are at risk.
Case definitions developed by WHO and the US Centers for
Disease Control and Prevention (CDC) are based on a history
of exposure and clinical evidence of illness (for example, fever,
headache, and myalgia). In the current epidemic areas, history
of exposure is now less useful.
Screening ensures the quick identification of potential cases
that need immediate isolation and investigation. People who
are asymptomatic and have epidemiological risk factors may
need to be monitored (for example, twice daily temperature
readings) for the duration of the incubation period, depending
on their risk of exposure. This ensures rapid recognition of
symptoms and immediate isolation.
Contacts
Contacts of infected patients (including healthcare workers and
household contacts) are at risk of infection if they were exposed
to the patient’s body fluids without protective equipment within
the past 21 days.2 3 Brief interactions, such as walking past a
person or moving through a hospital, do not constitute close
contact.
Epidemiological risk factors are divided into high risk, some
risk, low (but not zero) risk, and no identifiable risk categories.
A contact is defined by WHO as someone who has slept in the
same household as a patient; had direct physical contact with
the patient during the illness or at the funeral; touched the
patient’s body fluids, clothes, or bed linens during the illness;
or been breast fed by the patient (babies).27
What infection prevention and control
measures are used?
Boxes 1 and 2 list infection prevention and control measures
for healthcare workers and people living in affected areas. If
infection is suspected on the basis of initial screening, immediate
isolation is warranted before any further investigations. This is
crucial to reduce contact with other patients and healthcare
workers while the patient is being investigated. Isolation
measures should be continued until the patient has tested
negative.28
Personal protective equipment
The highest risk facing healthcare workers when looking after
infected patients is inadvertently touching their own faces or
neck under the face shield during patient care, and removing
(doffing) personal protective equipment (PPE; shown in fig 3⇓).
Healthcare workers should understand the following basic
principles of using PPE:
Donning—PPEmust be donned correctly in the proper order
before entering the patient care area. Because PPE cannot
be adjusted while in the patient care area, care should be
taken to ensure it is as comfortable as possible before
entering and that no skin is exposed. Donning activities must
be directly observed by a trained observer and a final check
performed before entering the patient care area
During patient care—PPE must remain in place and be
worn correctly for the duration of exposure to potentially
contaminated areas. PPE should not be adjusted during
patient care. Healthcare workers should regularly disinfect
gloved hands using an alcohol based hand rub or chlorinated
water, particularly after handling body fluids. If there is a
partial or total breach in PPE (such as gloves separating from
sleeves to leave exposed skin, a tear in an outer glove, or a
needlestick) during patient care, the healthcare worker must
move immediately to the doffing area to assess the exposure
and implement the facility exposure plan, if indicated
Doffing—Removal of used PPE is a high risk process that
requires a structured procedure, a trained observer, and a
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Box 1: Infection control measures for healthcare workers
Wear protective clothing
Practise proper infection control and sterilisation measures
Isolate suspected patients from each other (if possible), and patients with confirmed disease from those with suspected disease
Avoid direct contact with bodies of people who have died from Ebola, or suspected Ebola. During epidemics, avoid direct contact with
any dead body
Notify health officials if you have direct contact with the body fluids of an infected patient
Box 2: Infection control measures for people in affected areas
Practise careful hygiene (for example, wash hands with soap and water, alcohol based hand sanitiser, or diluted chlorine)
Avoid contact with body fluids
Do not handle items that have come into contact with an infected person’s body fluids (such as clothes, medical equipment, and needles)
Avoid funeral or burial rituals that require handling of the body of someone who has died from proven or suspected Ebola
Avoid contact with non-human primates and bats, including body fluids or raw meat prepared from these animals
Avoid hospitals in west Africa in which infected patients are being treated
Returning travellers, including healthcare workers, should follow national policy for surveillance and should monitor their health for 21
days and seek medical attention if symptoms develop, especially fever
designated area for removal to ensure protection. PPE must
be removed slowly and deliberately in the correct sequence
to reduce the possibility of self contamination or other
exposure. A stepwise process should be developed and used
during training and daily practice.29
The importance of a “buddy” when inside the patient care area,
and during donning and doffing, to ensure safe practice cannot
be overstated, together with guidance from independentmonitors
if available.
What other measures are needed if Ebola
virus disease is suspected?
If infection is suspected, the patient should be isolated and all
healthcare workers in contact with the patient should wear
personal protective equipment.
Contact tracing (family, friends, and work colleagues) is
essential. People who have been exposed to Ebola virus within
the past 21 days andwho are asymptomatic need to bemonitored
for the duration of the incubation period with twice daily
temperature readings to ensure rapid recognition of symptoms.
If symptoms are detected immediate isolation is essential.30
Healthcare workers suspected of being infected should be
isolated and treated in the same way as any other patient until
a negative diagnosis is confirmed.31 If exposure to body fluids
from a patient with suspected infection has occurred, the person
should immediately wash affected skin surfaces with soap and
water and irrigate mucous membranes with copious amounts
of water.
The patient’s home and any personal belongings that might have
been contaminated (such as clothes, linens, eating utensils, and
medical material) should be disinfected or disposed of (usually
by incineration). In epidemic areas, the patient’s home is sprayed
with 0.5% chorine solution.
What are the clinical features?
The case definition for Ebola virus infection is very broad and
includes a long list of possible differential diagnoses (fig 4⇓).
History
The initial assessment of a patient with suspected Ebola hinges
on two main factors: epidemiological risk (for example, living
or working in, or arrival from, an endemic area such as west
Africa in the past 21 days) and presence or history of a fever in
the past 24 hours. Apart from healthcare workers, people who
work with primates or bats from endemic areas or with high
risk clinical samples are also at high risk.
A detailed history helps to clarify the level of risk for infection
and to assess the possibility of other causes of an acute febrile
syndrome (fig 5⇓). Because malaria is still the most common
cause of febrile illness in returning travellers, the presence of
risk factors for acquiring malaria should be assessed (for
example, living or working in, or arriving from, an endemic
area; inadequate or absent chemoprophylaxis; not using
insecticides or bed nets).36 Infection control risk should be
assessed. Having determined that a patient may be infected, the
doctor needs to determine how infectious the patient currently
is. For example, the absence of vomiting or diarrhoea reduces
the risk of transmission, whereas uncontrolled diarrhoea greatly
increases the risk.
Precautionary isolation procedures and use of PPE are mandated
in symptomatic patients who may be at risk of infection until
the infection is confirmed or excluded. It is extremely important
to minimise the risk of transmission while investigating patients
(see later).28 37
Symptoms
There are typically three phases of illness, starting with a few
days of non-specific fever, headache, and myalgia, followed by
a gastrointestinal phase in which diarrhoea and vomiting,
abdominal symptoms, and dehydration are prominent. In the
second week, the patient may recover or deteriorate, with a third
phase of illness including collapse, neurological manifestations,
and bleeding, which is often fatal.38
Themost common symptoms reported between symptom onset
and case detection in the 2014 outbreak were fever (87.1%),
fatigue (76.4%), loss of appetite (64.5%), vomiting (67.6%),
diarrhoea (65.6%), headache (53.4%), abdominal pain (44.3%),
and unexplained bleeding (18%) (box 3).3 The high frequency
of vomiting and diarrhoea means that patients are often
dehydrated and hypovolaemic, particularly if they present late.
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Box 3: Typical symptoms of Ebola virus disease4
Fever ≥37.5°C*
Fatigue
Nausea or vomiting
Diarrhoea
Headache
Abdominal pain
Myalgia
Prostration
Sore throat
Unexplained bleeding or bruising
Spontaneous abortion or miscarriage
Hiccups
Rash
*The temperature threshold for “fever” level varies between different guidelines.39
Children present with similar symptoms to adults; however,
younger children are reported to have more respiratory (such
as cough and dyspnoea) and gastrointestinal symptoms, but less
bleeding and neurological signs, than adults.40 41 Anecdotally,
children under 4 years present initially with more subtle
symptoms before developing a fever and are often diagnosed
late.
Physical examination
A full physical examination should be undertaken with
precautionary isolation procedures and use of PPE. The aim of
examination is to exclude a focus for sepsis while looking for
signs of viral haemorrhagic fever (such as conjunctival injection,
purpuric rash, or other signs of bleeding).
Vital signs should be taken:
Fever (≥37.5°C)—Fever is the presenting symptom in about
90% of patients,3-42 and its presence is enough to raise
concern in the appropriate epidemiological context. Wide
variations in body temperature are seen during the course of
illness, with normothermia or hypothermia occurring in the
later stages of fatal infection.40-44 Some patients initially have
a low grade fever with no other symptoms
Blood pressure—Hypotension is a feature of preterminal
disease and shock. It is underdocumented in field studies,
owing to a lack of measuring equipment in endemic areas43
Pulse rate—Bradycardia may be present in the initial stages
of illness, whereas tachycardia may be seen in the later stages
of fatal infections43
Respiratory rate—Tachypnoea, along with tachycardia,
correlates with a more severe or advanced infection. It is
more likely to be caused by respiratory compensation of a
metabolic acidosis than respiratory involvement.43
Other possible findings include a maculopapular rash, bleeding,
hiccups, hepatomegaly, lymphadenopathy, and neurological
signs (box 4).43
Multi-organ dysfunction is common in advanced infection and
includes acute kidney injury, pancreatitis, adrenal failure, and
liver damage. Hepatitis is common, with aspartate
aminotransferase (AST) higher than alanine aminotransferase
(ALT), although jaundice is rare.23Renal dysfunction is common
in advanced disease but can be reversed with adequate fluid
resuscitation in the initial stages.23 In early disease it may be
caused by dehydration, but in later stages it may be a
consequence of disseminated intravascular coagulation or direct
damage to the kidneys by the Ebola virus.23 43Massive bleeding,
typically in the gastrointestinal tract (for example, bloody
diarrhoea or melaena), is usually seen only in fatal cases.43
Internal bleeding may be missed if there are no external signs.
Signs that indicate severe or advanced infection include hiccups,
hypotension, tachycardia, hepatomegaly, splenomegaly,
confusion, and seizures.
How is it investigated?
All specimens should be collected according to strict protocols.
Initial investigations
Themain confirmatory test for Ebola virus infection is a positive
Ebola RT-PCR.48 This test should be ordered in all patients with
suspected Ebola infection while the patient is isolated. The
results of RT-PCR are available 24-48 hours before those of
enzyme linked immunosorbent assay (ELISA) testing. In
Western settings, Ebola RT-PCR may be available only in
regional or national reference laboratories that have a high level
of biosafety precautions (category 4 facilities).8 In epidemic
settings and some European countries, category 4 laboratories
are set up locally, and RT-PCR is available four hours after the
sample has arrived. Viral RNA can be detected in the patient’s
blood by RT-PCR from day 3 to days 6-17 of symptoms. A
positive result implies that the patient is potentially infectious,
particularly if there is active diarrhoea, vomiting, or bleeding.
If negative, the test should be repeated within 48 hours because
viral load can be low and undetectable early in the illness.
Negative tests should also be repeated to rule out the diagnosis
(or confirm resolution of infection) if there is a strong suspicion
of Ebola.31Higher viral load correlates with adverse outcome.5-49
The choice of whether to test for Ebola depends on the patient’s
history and the risk of infection (fig 5).
Malaria is still the most common cause of fever in people who
live or work in, or travellers who have returned from, an
endemic area and should be ruled out.36 If a malaria rapid
diagnostic test is positive, malaria should be treated while
keeping in mind the possibility of a dual infection. Ebola virus
infection should be considered in a patient who does not respond
to antimalarial therapy.
It is recommended that confirmatory tests for Ebola virus
infection are performed before, or in tandemwith, differentiating
tests for other suspected conditions if Ebola virus infection is
suspected.
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Box 4: Physical examination findings
Maculopapular rash
Develops early in the course of illness in 25-52% of patients,43 although its occurrence has been much lower (5%) in the 2014 outbreak3
Often described as non-pruritic, erythematous, and maculopapular
May begin focally then become diffuse, generalised, and confluent. Some have described it as morbilliform
May become purpuric or petechial later on in the infection in patients with coagulopathy
May be difficult to discern in dark skinned patients
Bleeding
Bleeding manifestations (such as epistaxis, bleeding gums, haemoptysis, easy bruising, conjunctival bleeding, haematuria, and oozing
from injection or venipuncture sites) were present in 30-36% of infected patients in previous outbreaks,8-46 but they have been reported
in only 18% of patients in the 2014 outbreak3-47
Hiccups
A sign of advanced infection, typically seen in the last 2-3 days of fatal infections
Hepatomegaly or epigastric tenderness
Tender hepatomegaly, with the edge of the liver palpable below the rib cage, has been reported but is rare
Lymphadenopathy
Enlarged lymph nodes have been reported but are rare
Neurological signs
Confusion, depressed consciousness, encephalopathy, and seizures are rare but their presence indicates advanced infection
Other investigations
In the past, only a malaria screen and RT-PCR were
recommended because of the risk to laboratory workers.
However, it is now recognised that other investigations can be
done safely according to recommended guidelines, as long as
the laboratory is informed of the sample in advance, and the
samples are correctly packaged and retained at the end in case
the results are positive.28 42 Local protocols should be clear about
safe transport of samples to the local and referral laboratories
and safe handling on receipt in the local laboratory.
Box 5 outlines additional investigations that may add valuable
information to help guide further management, and that should
be ordered if possible.
How is it managed?
The mainstay of treatment is early recognition of infection,
coupled with effective isolation and best available supportive
care in a hospital setting.
High case fatality rates may be related to the supportive care
available in resource poor rural settings where outbreaks have
occurred They reflect the difficulties that patients in these
settings have in accessing basic medical care in a healthcare
structure that is overwhelmed.3 5
During the 2014 outbreak, comprehensive supportive
care—including organ support in intensive care units—was
available to cases imported to developed countries such as Spain,
Italy, Switzerland, Germany, France, Norway, the UK, and the
US.18-55 Despite this, deaths still occurred because of the lack of
specific effective treatments.
There is active debate about the suitability of moving patients
with advanced disease and a poor prognosis to intensive care,
where the risk for nosocomial infection may be high.52-57
However, failure to provide full supportive care to those with
suspected (not confirmed) infection may result in substandard
care for these patients, who may later be shown to have a
treatable disease such asmalaria. Local hospital protocols should
consider how this situation should be handled for patients with
suspected infection before possible transfer to the intensive care
unit, and for those who have already been transferred there.52-57
Isolation and infection control
Patients identified as being at risk of infection should
immediately be isolated in a room with private bathroom
facilities.
All attending healthcare personnel must wear PPE that conforms
with published protocols (fig 3).29 58All contaminated materials
(such as clothes and bed linens) should be treated as potentially
infectious.
Specimens for laboratory investigations (such as Ebola RT-PCR,
full blood count, serum creatinine and urea, liver function tests,
arterial blood gases, coagulation studies, blood cultures, and
investigations for other conditions such as malaria) should be
collected and sent off according to local and national protocols.
Judicious selection of investigations is needed to reduce the risk
of transmission to laboratory workers and other healthcare
personnel. Early placement of a central line (if possible) allows
blood to be taken and fluids to be given while minimising the
risk of needlestick injuries.
Fluid and electrolyte replacement
Vomiting and diarrhoea are common, so patients are often
dehydrated and hypovolaemic, particularly if they present late.
This is probably the cause of the high case fatality rates because
essential clinical monitoring (temperature, respiratory rate, pulse
rate, blood pressure, and fluid input and output) is often difficult
in resource poor settings.
Oral rehydration solutions can be used for patients who can
tolerate oral administration andwho are not severely dehydrated.
The volume of intravenous fluids needed should be assessed on
the basis of the clinical examination (level of dehydration, signs
of shock) and fluid losses (volume of diarrhoea or vomitus, or
both). Large volumes of fluid replacement (>10 L/day) may be
needed in febrile patients with diarrhoea.18
Access to point of care tests in the isolation facility means that
the patient’s biochemical status can be monitored more
efficiently and reduces the risks associated with specimen
transport.5 52 Electrolyte monitoring should be performed daily.
More frequent monitoring can be considered if large volumes
of intravenous fluids are being given or if severe biochemical
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Box 5: Other useful investigations when diagnosing Ebola virus disease
Antigen capture enzyme linked immunosorbent assay (ELISA) testing
A useful diagnostic test with high specificity, although it is not universally available
Most likely to give a positive result on days 3-6 of symptoms and can give widely variable results from days 7-1617
Can be used to confirm the diagnosis along with a positive reverse transcriptase-polymerase chain reaction result
Full blood count
Decreasing platelet count with marked lymphopenia can be seen in the initial stages of infection but is not diagnostic. This is often followed by
neutrophil leucocytosis in the later stages in patients who eventually recover, along with normalisation of thrombocytopenia. Leucocytosis may
persist and show immature forms
Patients with severe disease may show a progressive decline in platelet count as a manifestation of disseminated intravascular coagulation
(DIC)
Haemoglobin may be low in patients with bleeding manifestations43
Coagulation studies
Prolonged prothrombin time or activated partial thromboplastin time is associated with more severe infection and bleeding manifestations such
as DIC
D-dimer values are four times higher on days 6-8 of infection in patients who die than in those who survive50
Renal function and serum electrolytes
Raised serum creatinine or urea and abnormal electrolytes may indicate acute kidney injury; this may be seen at the end of the first week of
infection51
Some studies found hypokalaemia (associated with vomiting and diarrhoea) in about half of cases
Hypocalcaemia has been associated with fatal infection
Haematuria and proteinuria may also be seen in severe disease
Oliguria that does not respond to fluid resuscitation is a poor prognostic sign43
Arterial blood gases
Arterial or venous blood lactate, pH, and bicarbonate can help identify the degree of systemic hypoperfusion and guide fluid resuscitation in
acutely ill patients with signs of sepsis52
Raised lactate is a marker of tissue hypoperfusion and is an indicator of shock.
Liver function tests
Both ALT and AST are usually raised; most studies show that AST rises more than ALT—this is more suggestive of systemic tissue damage
rather than hepatocellular injury
The AST:ALT ratio peaked at 15:1 on days 6-8 of infection in fatal cases compared with days 5:1 in non-fatal cases43-50
Bilirubin, γ-glutamyl transferase, and alkaline phosphatase are often slightly raised. Greatly raised ALT and severe jaundice suggests an alternative
diagnosis (such as viral hepatitis)
Serum amylase
High concentrations have been reported in several studies and indicate the presence of pancreatitis, an indicator of severe infection43
Blood cultures
Negative blood cultures are helpful because they rule out other non-viral infectious causes (such as sepsis or enteric fever)
Ebola specific IgM and IgG antibodies
Useful in later stages of infection
IgM antibodies can appear in serum as early as day 2 after infection but results are variable up to day 9. They become negative between 30
and 168 days after symptom onset
An IgG response develops between days 6 and 18 and can persist for several years
A positive IgM or a rising IgG titre is strong evidence of recent Ebola virus infection17
Chest radiography
Useful in patients with respiratory symptoms
Pulmonary infiltrates are not typical of infection and suggest an alternative (or comorbid) diagnosis
May be difficult to arrange in an isolation unit and should be ordered judiciously to avoid contamination53
abnormalities are present. High blood lactate values are a reliable
measure of hypoperfusion and can help guide fluid
resuscitation.52 In patients with anuria who do not respond to
fluid resuscitation, renal replacement therapy has been used,18-59
although there are no trial data to support its effectiveness.
Major bleeding is uncommon, but is seen in advanced infection
that is usually fatal. When available, platelet and plasma
transfusions should be given according to local protocols.60
Symptomatic management
The following management strategies are recommended:
Fever and pain—Fever and pain should be treated with
paracetamol first. Opioid analgesics (such as morphine) are
preferable for more severe pain. Non-steroidal
anti-inflammatory drugs (including aspirin) should be
avoided because of the associated increased risk of bleeding
and potential for nephrotoxicity31
Nausea and vomiting—Oral or intravenous antiemetics
(such as ondansetron and metoclopramide) are
recommended31
Heartburn, dysphagia, and upper abdominal pain—An
antacid or proton pump inhibitor (such as omeprazole) may
be beneficial31
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g7348 doi: 10.1136/bmj.g7348 (Published 10 December 2014) Page 6 of 15
CLINICAL REVIEW
Seizures—Although uncommon, seizures can be seen in
advanced disease and pose a risk to healthcare workers
because they increase the risk of contact with the patient’s
body fluids. Contributing factors (such as high temperature,
hypoperfusion, and electrolyte disturbances) must be
recognised and corrected. A benzodiazepine can be used to
abort the seizure and can be given intramuscularly or rectally
if intravenous access is unavailable. An anticonvulsant (such
as phenobarbital) can be given for repeated seizures31
Agitation—Although uncommon, agitation can occur in
advanced disease. It may be associated with encephalopathy
or may be a direct effect of the virus on the brain. Judicious
use of a sedative (such as haloperidol or a benzodiazepine)
will help to keep the patient calm and prevent needlestick
injuries in healthcare workers31
Sepsis and septic shock—Management follows the same
principles as for bacterial sepsis.61 It should include broad
spectrum antibiotics (such as ceftriaxone,
piperacillin-tazobactam, or meropenem) in the first hour
after sending blood cultures, rapid intravenous fluid
resuscitation with assessment of response, appropriate airway
management and oxygen administration, and monitoring of
urine output preferably by urethral catheterisation. Broad
spectrum antibiotics in these patients are used to target the
presumed translocation of gut organisms. This is not backed
by any evidence. Blood cultures are difficult to perform
safely in infected patients.
In the absence of a response to initial management, inotropic
support should be considered, preferably through a central
venous catheter in an intensive care unit where invasive
monitoring enables more aggressive correction of fluids,
electrolytes, and acid-base balance.52 54
Malaria should be tested for and treated with appropriate
antimalarial therapy. In endemic settings all patients in Ebola
treatment centres are treated for malaria routinely.5-47
Are there any emerging treatments?
Although experimental treatments for Ebola virus infection are
under development, they have not yet been fully tested for safety
or effectiveness.62 63
Convalescent whole blood or plasma
There is limited evidence from past outbreaks that transfusion
of blood from convalescent patients might be beneficial in the
acute phase of infection and may reduce mortality.46 63Trials are
planned.62 64
ZMapp
The best known emerging treatment so far, ZMapp, is a
combination of three humanisedmonoclonal antibodies targeted
at three Ebola virus glycoprotein epitopes and is engineered for
expression in tobacco plants.62-66 Before the current 2014
outbreak, ZMapp had proved protective when given to
non-human primates 24-48 hours after infection. Another study
showed that the drug could rescue non-human primates when
treatment was started up to five days after infection.67 It has not
yet been tested in humans for safety or efficacy; however, very
limited stock (seven doses) was made available to infected
patients during the current outbreak, and only one patient died.
Despite its potential, numbers are too small to make any
conclusions about the drug’s safety and efficacy. More doses
are not currently available to conduct larger trials, but
development is being accelerated with support from the US
government.68
TKM-Ebola
TKM-Ebola consists of a combination of small interfering RNAs
that target Ebola virus RNA polymerase L, formulated with
lipid nanoparticle technology. It has been shown to be protective
in non-human primates and is effective against Marburg virus
in guinea pigs and monkeys.62-71 The US Food and Drug
Administration has granted expanded access to this drug under
an Investigational New Drug application. Under emergency
protocols, it has been given to a small number of patients.
Brincidofovir
Formerly known as CMX-001, brincidofovir is currently
undergoing phase III trials for the treatment of cytomegalovirus
and adenovirus. It also shows activity against Ebola virus in
vitro. The drug has been used in patients with Ebola virus
infection in the US under Emergency Investigational NewDrug
applications approved by the FDA. Trials are planned in the
near future in west Africa.62-64
Favipiravir
Formerly known as T-705, favipiravir selectively inhibits viral
RNA dependent RNA polymerase. It is active against influenza
viruses, West Nile virus, yellow fever virus, foot and mouth
disease virus, as well as other flaviviruses, arenaviruses,
bunyaviruses, and alphaviruses. The drug is approved in Japan
for influenza pandemics and is effective against Ebola virus in
mouse models.62-72Human trials are due to start in west Africa.64
BCX-4430
BCX-4430 is an adenosine analogue that is active against Ebola
virus in rodents. It is thought to act through the inhibition of
viral RNA dependent RNA polymerase. It is active against
flaviviruses, bunyaviruses, arenaviruses, and paramyxoviruses.
The drug has been shown to be protective in non-human
primates and rodents, even when given 48 hours after infection
with filoviruses63 73; however, no human studies have been
performed.
AVI-7537
AVI-7537 consists of antisense phosphorodiamidatemorpholino
oligomers (PMOs) that target the Ebola virus VP24 gene. It
confers a survival benefit to Ebola virus infected non-human
primates.63 74 AVI-6002 consists of two PMOs (AV-7537 and
AV-7539, which targets the VP35 gene). AV-6002 has
undergone phase I clinical studies.
Other agents
Interferons have been used in the past, with uncertain benefit.16 63
Therapeutic agents used for other diseases, such as amiodarone,
clomiphene, and chloroquine, inhibit Ebola virus interactions
with human cells in models, and amiodarone will shortly be
trialled in west Africa.62 75
Vaccines
Two experimental vaccines are currently undergoing trials.62 63
cAd3-ZEBOV is a chimpanzee derived adenovirus vector with
an Ebola virus gene inserted.76Trials are under way in the United
Kingdom, United States, Switzerland, and some African
countries. rVSV-ZEBOV is an attenuated vesicular stomatitis
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virus with one of its genes replaced by an Ebola virus gene.
Human trials have started in the US.
What is the prognosis?
The natural clinical course of Ebola virus infection varies
markedly between the different viral species and according to
the level of supportive medical care available. The most lethal
species is Zaire ebolavirus, which has a reported case fatality
rate of up to 90%. The rate in the current 2014 outbreak is less
than this and is estimated at 60-70%, although accurate data are
biased by poor record keeping and registration.3Most epidemics
have occurred in resource poor settings with little supportive
care, and the case fatality rate in high income settings could be
less than 40%.52 Mortality is higher in younger children (<5
years) and adults over 40 years than in adolescents and young
adults.3-51 An observational study during an outbreak in 1995
showed a marked decrease in the case fatality rate from 93% to
69% between the initial and final phases of the outbreak.77 This
suggests that later cases were recognised earlier and possibly
received higher quality care. Pregnant women have a high
incidence of miscarriage and the infection is almost always fatal
in these women.38-80
Infection course
Patients who die tend to develop clinical signs early on in the
infection, with death, usually attributed to shock andmulti-organ
failure, typically occurring between days 6 and 16 (median 9
days) from symptom onset.19-82 Patients who eventually recover
exhibit isolated fever for several days with improvement
typically around days 6-11. A high viral load at presentation is
correlated with mortality.5-49Biomarkers as prognostic indicators
require further study.51 81
Recovery and convalescence
Patients who live through the second week of infection have
more than a 75% chance of surviving.43 Patients are usually
discharged from the isolation facility when they are ambulant,
able to self care, have no serious symptoms (such as diarrhoea,
vomiting, or bleeding), and have two negative Ebola RT-PCR
results taken 48 hours apart.47
Patients who survive usually have a protracted recovery
characterised by asthenia, weight loss, and migratory arthralgia.
Skin desquamation and transient hair loss are also common.
Late manifestations during convalescence are uncommon but
include uveitis, orchitis, myelitis, parotitis, pancreatitis, hepatitis,
psychosis, hearing loss and tinnitus.44 The cause of these
manifestations is unclear but they might be related to immune
complex phenomena.
Survivors of infection probably have lifetime immunity to the
same strain of Ebola virus. Such patients have therefore been
invaluable in caring for those with active infections.
What advice should patients be given during
recovery?
Patients should be educated about the likely course of
convalescence and the possibility of long term complications.
There are no specific requirements for monitoring after
discharge; however, eligible patients may be asked to donate
blood from 28 days after discharge to be used in the treatment
of patients with active infection.
Male patients should be reminded about the importance of using
condoms to prevent sexual transmission in the three months
after resolution of infection.15-17 Women should be advised not
to breast feed during infection.15
Survivors and orphans of those who died from the disease face
stigma and ostracism in many communities. This—along with
substantial associated psychological disturbance—was reported
after previous outbreaks,83 84 and it is an increasing problem in
the 2014 outbreak.
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Fig 1 Infographic on Ebola virus disease
Fig 2 Map of Ebola virus outbreaks 1976-2014 (Centers for Disease Control and Prevention)
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g7348 doi: 10.1136/bmj.g7348 (Published 10 December 2014) Page 12 of 15
CLINICAL REVIEW
Fig 3Healthcare worker in personal protective equipment at an Ebola treatment centre in Sierra Leone, 2014 (with permission
from Chris Lane, Public Health England/WHO)
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Fig 4 Differential diagnosis. Confirmatory tests should be performed before, or in tandem with, differentiating tests if Ebola
virus infection is suspected
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Fig 5 Diagnostic pathway for the investigation of suspected Ebola virus infection (produced by the BMJ Evidence Centre)
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